Skip to main content
. Author manuscript; available in PMC: 2013 Aug 28.
Published in final edited form as: Cancer Res. 2012 Oct 16;72(24):6502–6511. doi: 10.1158/0008-5472.CAN-12-1909

Figure 3.

Figure 3

shNedd9 alleviates de novo lung cancer progression evoked by Lkb1 deficiency. A, pathologic photos of lung tumors from KrasG12D, Lkb1L/L mice at 21 weeks post viral infection of Ctrl-Cre or shNedd9-Cre (7 mice per group). Scale bars, 500 μm (top) and 50 μm (bottom). B, statistic analyses of well- or poorly differentiated lung tumors from KrasG12D, Lkb1L/L mice receiving Ctrl-Cre or shNedd9-Cre infection. Data are shown as mean ± SEM. *, P < 0.05 (n = 7). C, Ki-67 immunostaining of lung sections from KrasG12D, Lkb1L/L mice virally infected with Ctrl-Cre or shNedd9-Cre. Scale bars, 50 μm. D, bar diagrams illustrate the percentage of Ki-67–positive staining in lung tumors from KrasG12D, Lkb1L/L mice virally infected with either Ctrl-Cre or shNedd9-Cre. The percentage of Ki-67 staining was quantified by counting more than 1,000 nuclei staining tumor cells. Data are shown as mean ± SEM. ***, P < 0.001.